Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
Journal
The Journal of biological chemistry
Journal Volume
299
Journal Issue
6
Date Issued
2023-06
Author(s)
Hong, Xuan
Hsieh, Min-Tsang
Tseng, Tzu-Yu
Lin, Hui-Yi
Chang, Hung-Chih
Yau, Sir-Theng
Cheng, Wei-Chung
Ke, Baozhen
Liao, Hsiao-Hui
Wu, Chih-Ying
Liu, An-An
Wu, Meei-Maan
Huang, Kuo-Yen
Kuo, Sheng-Chu
Hung, Mien-Chie
Lee, Pei-Chih
Abstract
Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) patients often respond to EGFR tyrosine kinase inhibitors (TKIs) initially but eventually develop resistance to TKIs. The switch of EGFR downstream signaling from TKI-sensitive to TKI-insensitive is a critical mechanism-driving resistance to TKIs. Identification of potential therapies to target EGFR effectively is a potential strategy to treat TKI-resistant LUADs. In this study, we developed a small molecule diarylheptanoid 35d, a curcumin derivative, that effectively suppressed EGFR protein expression, killed multiple TKI-resistant LUAD cells in vitro, and suppressed tumor growth of EGFR-mutant LUAD xenografts with variant TKI-resistant mechanisms including EGFR C797S mutations in vivo. Mechanically, 35d triggers heat shock protein 70-mediated lysosomal pathway through transcriptional activation of several components in the pathway, such as HSPA1B, to induce EGFR protein degradation. Interestingly, higher HSPA1B expression in LUAD tumors associated with longer survival of EGFR-mutant, TKI-treated patients, suggesting the role of HSPA1B on retarding TKI resistance and providing a rationale for combining 35d with EGFR TKIs. Our data showed that combination of 35d significantly inhibits tumor reprogression on osimertinib and prolongs mice survival. Overall, our results suggest 35d as a promising lead compound to suppress EGFR expression and provide important insights into the development of combination therapies for TKI-resistant LUADs, which could have translational potential for the treatment of this deadly disease.
Subjects
EGFR; EGFR mutation; TKI resistance; TKI-insensitive EGFR signaling; lung adenocarcinoma; lung cancer
SDGs
Type
journal article